Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Agilis Biotherapeutics

Request full access

Welcome to Agilis - Agilis Website

New York City, United StatesFounded 2013Biotechnology

About Agilis Biotherapeutics

Agilis Biotherapeutics, founded in 2013, operated as a biotechnology firm concentrated on developing DNA-based therapeutics for rare, life-threatening genetic diseases affecting the central nervous system (CNS). The company's core strategy involved creating treatments to rectify underlying genetic defects by introducing a corrected gene copy to targeted cells. This approach aimed to provide lasting efficacy for patients with debilitating and often fatal conditions that had few or no treatment options.

The company's business model was centered on the research and development of a pipeline of gene therapies, with the ultimate goal of commercialization and providing these treatments to patients globally. Agilis focused on rare monogenic diseases, which are caused by the malfunction of a single gene. Its primary clients were patients suffering from these specific rare CNS disorders. The company's lead candidate, GT-AADC, was developed for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency, a severe CNS disorder caused by mutations in the DDC gene that leads to a lack of motor control. Clinical studies of GT-AADC showed that a single treatment resulted in significant and durable gains in motor and cognitive functions over several years. The pipeline also included preclinical programs for Friedreich's ataxia (GT-FA) and Angelman syndrome (GT-AS).

A key figure in the company's later stage was Dr. Mark Pykett, who served as President and CEO. In July 2018, PTC Therapeutics announced its agreement to acquire Agilis Biotherapeutics, a deal that was finalized in August 2018. The acquisition was valued at approximately $200 million upfront, comprising $50 million in cash and $150 million in PTC stock, with potential future payments tied to developmental, regulatory, and commercial milestones. The strategic acquisition allowed PTC Therapeutics to absorb Agilis's specialized gene therapy platform, its experienced team, and its pipeline, significantly enhancing PTC's capabilities in treating rare diseases.

Source: Dealroom company data

At a glance

Status
Acquired
Open positions
None listed
Dealroom signal
18.7/100
Client focus
B2B, B2C

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Jul 2018 $200M $200M PTC Therapeutics —
EARLY VCEquity / VC Feb 2017 $13M $51M Sands Capital Management —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Agilis Biotherapeutics website traffic

Latest recorded traffic for Agilis Biotherapeutics is 100 monthly website visits, down 33.3% over the last three months.

Latest monthly visits100 3-month web change-33.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Agilis Biotherapeutics in the New York City ecosystem

Live from Dealroom

The Agilis Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Sands Capital Management

Other known investors1 additional known investor

  • PTC Therapeutics
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · New York City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Agilis Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Agilis Biotherapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.